Phase_VB I_PP Dose_NP Escalation_NP Trial_NP Evaluating_VBG the_DT Pharmacokinetics_NP ,_, Anti-Human_NP Cytomegalovirus_NP (_( HCMV_NP )_) Activity_NN ,_, and_CC Safety_NP of_IN 1263W94_NP in_IN Human_NP Immunodeficiency_NN Virus-Infected_NP Men_NP with_IN Asymptomatic_NP HCMV_NP Shedding_NP 1263W94_NP [_SYM maribavir_NN ;_: 5,6-dichloro-2-(isopropylamino)-1,beta-l-ribofuranosyl-1-H-benzimidazole_NN ]_SYM is_VBZ a_DT novel_JJ benzimidazole_NN compound_NN for_IN treatment_NN of_IN human_JJ cytomegalovirus_NN (_( HCMV_NP )_) infection_NN and_CC disease_NN ,_, with_IN potent_JJ in_IN vitro_NN activity_NN against_IN HCMV_NP and_CC good_JJ oral_JJ bioavailability_NN ._SENT A_DT phase_NN I_PP study_VBP was_VBD conducted_VBN to_TO determine_VB the_DT pharmacokinetics_NNS (_( PK_NP )_) ,_, anti-HCMV_NP activity_NN ,_, and_CC safety_NN of_IN 1263W94_JJ administered_VBN as_IN multiple_JJ oral_JJ doses_NNS to_TO human_JJ immunodeficiency_NN virus_NN type_NN 1-infected_JJ adult_JJ male_JJ subjects_NNS with_IN asymptomatic_JJ HCMV_NP shedding_NN ._SENT Subjects_NNS received_VBD one_CD of_IN six_CD dosage_NN regimens_NNS (_( 100_CD ,_, 200_CD ,_, or_CC 400_CD mg_NN three_CD times_NNS a_DT day_NN ,_, or_CC 600_CD ,_, 900_CD ,_, or_CC 1,200_CD mg_NN twice_RB a_DT day_NN )_) or_CC a_DT placebo_NN for_IN 28_CD days_NNS ._SENT 1263W94_NP demonstrated_VBD linear_JJ PK_NP ,_, with_IN steady-state_NN plasma_NN 1263W94_JJ profiles_NNS predictable_JJ based_VBN on_IN single-dose_JJ data_NNS ._SENT 1263W94_NP was_VBD rapidly_RB absorbed_VBN following_VBG oral_JJ dosing_VBG ,_, and_CC values_NNS for_IN the_DT maximum_JJ concentration_NN of_IN the_DT drug_NN in_IN plasma_NN and_CC the_DT area_NN under_IN the_DT concentration-time_JJ curve_NN increased_VBN in_IN proportion_NN to_TO the_DT dose_NN ._SENT 1263W94_NP demonstrated_VBD in_IN vivo_JJ anti-HCMV_NP activity_NN in_IN semen_NN at_IN all_DT of_IN the_DT dosage_NN regimens_NNS tested_VBD ,_, with_IN mean_JJ reductions_NNS in_IN semen_NN HCMV_NP titers_NNS of_IN 2.9_CD to_TO 3.7_CD log10_NN PFU/ml_NN among_IN the_DT four_CD regimens_NNS evaluated_VBN for_IN anti-HCMV_NP activity_NN ._SENT 1263W94_NP was_VBD generally_RB well_RB tolerated_VBN ;_: taste_NN disturbance_NN was_VBD the_DT most_RBS frequently_RB reported_VBN adverse_JJ event_NN over_IN the_DT 28-day_JJ dosing_VBG period_NN ._SENT Infection_NN with_IN human_JJ cytomegalovirus_NN (_( HCMV_NP )_) is_VBZ common_JJ ,_, with_IN seroprevalence_NN ranging_VBG from_IN approximately_RB 50_CD to_TO 60_CD %_NN of_IN adults_NNS in_IN Western_NP Europe_NP and_CC the_DT United_NP States_NPS to_TO as_RB much_JJ as_IN 100_CD %_NN of_IN some_DT adult_JJ populations_NNS ._SENT In_IN immunocompetent_JJ HCMV-infected_JJ individuals_NNS ,_, the_DT virus_NN normally_RB remains_VBZ latent_JJ and_CC does_VBZ not_RB constitute_VB a_DT major_JJ health_NN risk_NN ._SENT However_RB ,_, HCMV_NP infection_NN can_MD be_VB a_DT serious_JJ complication_NN in_IN immunologically_RB immature_JJ individuals_NNS ,_, such_JJ as_IN neonates_NNS ,_, or_CC in_IN immunocompromised_JJ individuals_NNS ,_, such_JJ as_IN solid-organ_JJ transplant_NN recipients_NNS ,_, bone_NN marrow_NN transplant_NN recipients_NNS ,_, or_CC people_NNS with_IN AIDS_NP ._SENT There_EX are_VBP six_CD currently_RB approved_VBN therapies_NNS in_IN the_DT United_NP States_NPS for_IN treatment_NN or_CC prevention_NN of_IN systemic_JJ HCMV_NP infection_NN or_CC HCMV_NP retinitis_NN associated_VBN with_IN AIDS_NP ._SENT Treatment_NN of_IN systemic_JJ HCMV_NP infection_NN requires_VBZ administration_NN of_IN ganciclovir_NP ,_, foscarnet_NN ,_, or_CC cidofovir_NN ._SENT After_IN induction_NN therapy_NN with_IN intravenously_RB (_( i.v._NN )_) administered_VBN agents_NNS or_CC oral_JJ valganciclovir_NN ,_, maintenance_NN therapy_NN can_MD be_VB provided_VBN by_IN oral_JJ ganciclovir_NP or_CC valganciclovir_NP ._SENT An_DT intravitreal_JJ implant_NN of_IN ganciclovir_NP is_VBZ available_JJ for_IN treatment_NN of_IN HCMV_NP retinitis_NN ;_: however_RB ,_, the_DT implant_NN is_VBZ insufficient_JJ for_IN controlling_VBG systemic_JJ disease_NN and_CC must_MD be_VB used_VBN together_RB with_IN systemic_JJ therapy_NN ,_, such_JJ as_IN oral_JJ or_CC i.v._JJ ganciclovir_NP or_CC oral_JJ valganciclovir_NN ._SENT Fomivirsen_NP ,_, administered_VBN by_IN intravitreal_JJ injection_NN ,_, is_VBZ approved_VBN as_IN a_DT second-line_NN therapy_NN for_IN treatment_NN of_IN HCMV_NP retinitis_NN in_IN subjects_NNS who_WP cannot_MD tolerate_VB or_CC fail_VB to_TO respond_VB to_TO first-line_NN therapy_NN ._SENT Disadvantages_NNS of_IN the_DT currently_RB approved_VBN therapies_NNS include_VBP treatment-limiting_JJ toxicities_NNS ,_, such_JJ as_IN bone_NN marrow_NN suppression_NN (_( ganciclovir_NP )_) and_CC nephrotoxicity_NN (_( foscarnet_NN and_CC cidofovir_NN )_) ,_, limited_JJ penetration_NN to_TO target_NN sites_NNS ,_, and_CC inconvenient_JJ i.v._NN dosing_VBG or_CC poor_JJ oral_JJ bioavailability_NN (_( oral_JJ ganciclovir_NP )_) ._SENT Thus_RB ,_, there_EX is_VBZ a_DT need_NN for_IN a_DT safe_JJ and_CC effective_JJ oral_JJ therapy_NN for_IN the_DT treatment_NN and_CC prevention_NN of_IN HCMV_NP disease_NN ._SENT 1263W94_NN [_SYM maribavir_NN ;_: 5,6-dichloro-2-(isopropylamino)-1,beta-l-ribofuranosyl-1-H-benzimidazole_NN ]_SYM is_VBZ a_DT novel_JJ benzimidazole_NN compound_NN shown_VBN to_TO have_VB antiviral_JJ activity_NN against_IN HCMV_NP in_IN vitro_NP ._SENT 1263W94_NP does_VBZ not_RB require_VB intracellular_JJ activation_NN and_CC has_VBZ demonstrated_VBN activity_NN against_IN clinical_JJ isolates_NNS resistant_JJ to_TO ganciclovir_NP or_CC foscarnet_NP ._SENT 1263W94_NP was_VBD safely_RB administered_VBN as_IN single_JJ oral_JJ doses_NNS of_IN 50_CD to_TO 1,600_CD mg_NN to_TO healthy_JJ and_CC human_JJ immunodeficiency_NN virus_NN (HIV)-infected_VBD adults_NNS in_IN two_CD separate_JJ studies_NNS (_( L._NP Wang_NP ,_, L._NP ,_, R._NP Peck_NP ,_, Y._NP Yin_NP ,_, J._NP Allanson_NP ,_, R._NP Wiggs_NP ,_, and_CC M._NP Wire_NP ,_, unpublished_JJ data_NNS )_) ._SENT In_IN the_DT two_CD single_JJ oral_JJ dose_NN escalation_NN studies_NNS ,_, 1263W94_JJ pharmacokinetics_NNS (_( PK_NP )_) were_VBD dose_NN proportional_JJ over_IN the_DT dose_NN range_NN tested_VBD ,_, 1263W94_JJ was_VBD highly_RB metabolized_VBN (_( similar40_JJ %_NN of_IN the_DT dose_NN was_VBD recovered_VBN in_IN the_DT urine_NN as_IN metabolite_NN ,_, and_CC <2_JJ %_NN was_VBD recovered_VBN as_IN the_DT parent_NN drug_NN )_) ,_, and_CC 1263W94_NP was_VBD highly_RB (_( similar98.5_JJ %_NN )_) protein_NN bound_VBN ._SENT Previous_JJ in_IN vitro_NP human_JJ liver_NN microsomal_JJ studies_NNS suggested_VBD that_IN CYP3A4_NP was_VBD the_DT primary_JJ enzyme_NN responsible_JJ for_IN 1263W94_JJ metabolism_NN (_( N_NP dealkylation_NP )_) (_( Wang_NP et_FW al._FW ,_, unpublished_JJ )_) ._SENT Indeed_RB ,_, similar40_JJ %_NN of_IN the_DT 1263W94_JJ dose_NN recovered_VBN in_IN the_DT urine_NN was_VBD recovered_VBN as_IN the_DT N-dealkylated_JJ metabolite_NN (_( Wang_NP et_FW al._FW ,_, unpublished_JJ )_) ._SENT We_PP conducted_VBD a_DT phase_NN I_PP dose_VBP escalation_NN study_NN to_TO evaluate_VB the_DT PK_NP ,_, anti-HCMV_NP activity_NN ,_, and_CC safety_NN of_IN 1263W94_JJ in_IN HIV-1-infected_JJ adult_NN males_NNS with_IN asymptomatic_JJ HCMV_NP shedding_NN in_IN urine_NN and_CC semen_NN ._SENT Quantitative_JJ reductions_NNS in_IN semen_NN HCMV_NP concentrations_NNS are_VBP dose_NN responsive_JJ and_CC predictive_JJ of_IN clinical_JJ efficacy_NN (_( -_: )_) ._SENT Study_NN population_NN and_CC investigative_JJ sites_NNS ._SENT |_SYM The_DT study_NN population_NN consisted_VBN of_IN HIV-1-infected_JJ males_NNS ._SENT Eligibility_NN criteria_NNS were_VBD as_RB follows_VBZ :_: all_DT subjects_NNS had_VBD to_TO be_VB >=18_JJ years_NNS old_JJ ,_, have_VBP a_DT life_NN expectancy_NN of_IN >6_JJ months_NNS ,_, and_CC be_VB stable_JJ on_IN all_DT chronically_RB administered_VBN therapy_NN for_IN HIV_NP infection_NN and_CC opportunistic_JJ infections_NNS for_IN at_IN least_JJS 1_CD month_NN ._SENT Subjects_NNS were_VBD stratified_VBN into_IN two_CD groups_NNS ,_, main_JJ and_CC satellite_NN ,_, on_IN the_DT basis_NN of_IN semen_NN and_CC urine_NN HCMV_NP culture_NN results_NNS prior_RB to_TO study_VB entry_NN ._SENT Subjects_NNS with_IN a_DT semen_NN HCMV_NP concentration_NN of_IN >=5,000_NP PFU/ml_NP and_CC with_IN an_DT HCMV-positive_JJ urine_NN culture_NN within_IN 30_CD days_NNS of_IN study_NN entry_NN (_( day_NN 1_CD )_) were_VBD enrolled_VBN in_IN the_DT main_JJ group_NN for_IN evaluation_NN of_IN the_DT PK_NP ,_, anti-HCMV_NP activity_NN ,_, and_CC safety_NN of_IN 1263W94_NP ._SENT There_EX was_VBD no_DT requirement_NN for_IN detectable_JJ HCMV_NP infection_NN in_IN subjects_NNS enrolled_VBN in_IN the_DT satellite_JJ group_NN for_IN evaluation_NN of_IN 1263W94_NP PK_NP and_CC safety_NN ._SENT Subjects_NNS enrolled_VBN in_IN the_DT satellite_NN group_NN were_VBD required_VBN to_TO have_VB a_DT CD4+_NP cell_NN count_NN of_IN <150_JJ cells/mm3_NN or_CC <10_NN %_NN of_IN total_JJ lymphocytes_NNS ._SENT For_IN subjects_NNS with_IN a_DT CD4+_NP cell_NN count_NN of_IN <100_JJ cells/mm3_NN or_CC with_IN signs_NNS or_CC symptoms_NNS of_IN HCMV_NP disease_NN ,_, an_DT indirect_JJ fundoscopic_JJ examination_NN was_VBD performed_VBN by_IN an_DT ophthalmologist_NN to_TO rule_VB out_RP HCMV_NP retinitis_NN ._SENT The_DT following_VBG exclusion_NN criteria_NNS applied_VBN to_TO all_DT subjects_NNS :_: active_JJ HCMV_NP disease_NN or_CC history_NN of_IN HCMV_NP disease_NN ;_: visual_JJ symptoms_NNS suggestive_JJ of_IN HCMV_NP disease_NN unless_IN HCMV_NP disease_NN was_VBD excluded_VBN by_IN ophthalmoscopic_JJ examination_NN ;_: treatment_NN with_IN ganciclovir_NP ,_, foscarnet_NN ,_, cidofovir_NN ,_, or_CC investigational_JJ anti-HCMV_NP drugs_NNS within_IN 2_CD months_NNS prior_RB to_TO study_NN entry_NN (_( day_NN 1_CD )_) ;_: treatment_NN with_IN interferons_NNS ,_, immunomodulatory_JJ agents_NNS ,_, or_CC HCMV_NP hyperimmune_NN globulin_NN within_IN 1_CD month_NN prior_JJ to_TO study_NN entry_NN (_( day_NN 1_CD )_) ;_: active_JJ hepatitis_NN ,_, obstructive_JJ hepatobiliary_JJ disease_NN ,_, or_CC cirrhosis_NN ;_: gastrointestinal_JJ disorders_NNS that_WDT could_MD interfere_VB with_IN oral_JJ dosing_VBG or_CC drug_NN absorption_NN or_CC that_WDT might_MD indicate_VB HCMV_NP disease_NN ;_: known_VBN history_NN of_IN lactose_NN intolerance_NN ;_: diagnosis_NN of_IN chronic_JJ diseases_NNS that_WDT could_MD compromise_VB the_DT safety_NN or_CC compliance_NN of_IN the_DT subject_NN ;_: treatment_NN with_IN radiation_NN therapy_NN or_CC systemic_JJ therapy_NN for_IN visceral_JJ malignancy_NN within_IN 2_CD months_NNS prior_RB to_TO study_NN entry_NN (_( day_NN 1_CD )_) ,_, or_CC anticipated_JJ need_NN for_IN such_JJ treatment_NN during_IN the_DT study_NN period_NN ;_: participation_NN in_IN an_DT investigational_JJ trial_NN or_CC treatment_NN with_IN an_DT investigational_JJ therapy_NN within_IN 2_CD months_NNS (_( anti-HCMV_NP therapy_NN )_) or_CC 1_CD month_NN (_( other_JJ therapy_NN )_) prior_RB to_TO study_NN entry_NN (_( day_NN 1_CD )_) ;_: abnormal_JJ laboratory_NN values_NNS within_IN 14_CD days_NNS of_IN study_NN entry_NN (_( day_NN 1_CD )_) ,_, notably_RB ,_, hemoglobin_NN of_IN <8.5_JJ g/dl_NN ,_, a_DT neutrophil_JJ count_NN of_IN <750_JJ cells/mm3_NN ,_, a_DT platelet_NN count_NN of_IN <=50,000_cells/mm3, 4_CD times_NNS the_DT upper_JJ limit_NN of_IN normal_JJ ,_, total_JJ bilirubin_NN of_IN >2_JJ mg/dl_NN ,_, or_CC estimated_JJ creatinine_NN clearance_NN of_IN <50_ml/min; 103_CD copies/ml_NN ._SENT PCR_NP amplification_NN was_VBD performed_VBN in_IN a_DT 96-well_NN plate_NN by_IN using_VBG an_DT ABI_NP Thermal_NP Cycler_NP 9600_NP (_( Perkin-Elmer_NP Applied_NP Biosystems_NP ,_, Foster_NP City_NP ,_, Calif._NP )_) ,_, with_IN the_DT following_VBG amplification_NN conditions_NNS :_: 50C_NN for_IN 10_CD min_NN ;_: amplification_NN at_IN 96C_NN for_IN 30_CD s_NNS and_CC 65C_JJ for_IN 30_CD s_NNS for_IN 30_CD cycles_NNS ;_: and_CC a_DT hold_NN at_IN 72C_NP for_IN no_DT more_JJR than_IN 2_CD h._JJ Quantitative_JJ detection_NN of_IN the_DT PCR_NP products_NNS was_VBD based_VBN on_IN colorimetric_JJ detection_NN of_IN an_DT avidin-horseradish_JJ peroxidase_NN complex_NN bound_VBN to_TO the_DT biotin_NN moiety_NN of_IN the_DT HCMV_NP DNA_NP primer_NN ._SENT Determination_NN of_IN HCMV_NP sensitivity_NN to_TO 1263W94_JJ by_IN plaque_NN reduction_NN assay_NN ._SENT |_SYM HCMV_NP isolates_NNS from_IN semen_NN and_CC urine_NN samples_NNS were_VBD shipped_VBN either_RB as_IN growing_VBG ,_, infected_JJ cells_NNS or_CC as_IN frozen_JJ stocks_NNS ._SENT Infected_JJ cells_NNS were_VBD plated_VBN on_IN MRC-5_NP cells_NNS and_CC grown_VBN for_IN at_IN least_JJS 2_CD passages_NNS until_IN 70_CD to_TO 90_CD %_NN of_IN cells_NNS showed_VBD characteristic_JJ HCMV_NP cytopathic_JJ effects_NNS ._SENT Infected_JJ cell_NN stocks_NNS were_VBD made_VBN and_CC titered_VBN ._SENT Plaque_NN reduction_NN assays_NNS were_VBD performed_VBN to_TO determine_VB whether_IN clinical_JJ isolates_NNS had_VBD acquired_VBN resistance_NN to_TO 1263W94_JJ ._SENT Clinical_JJ isolates_NNS were_VBD analyzed_VBN as_IN cell-associated_JJ virus_NN ,_, and_CC AD169_NP was_VBD analyzed_VBN as_IN cell-free_JJ supernatant_JJ virus_NN ._SENT Drug_NN concentrations_NNS were_VBD tested_VBN in_IN triplicate_NN ,_, and_CC the_DT mean_JJ values_NNS were_VBD determined_VBN for_IN each_DT clinical_JJ isolate_NN at_IN each_DT concentration_NN ._SENT 1263W94_NP was_VBD assayed_VBN at_IN seven_CD concentrations_NNS ,_, ranging_VBG from_IN 0.01_CD to_TO 30_CD muM_NN ,_, as_RB previously_RB described_VBN ._SENT RESULTS_NNS |_SYM Subject_JJ population_NN ._SENT |_SYM Seventy-eight_NN subjects_NNS were_VBD enrolled_VBN in_IN the_DT study_NN ._SENT Of_IN these_DT ,_, 28_CD were_VBD assigned_VBN to_TO the_DT main_JJ group_NN and_CC 50_CD were_VBD assigned_VBN to_TO the_DT satellite_NN group_NN ._SENT The_DT number_NN of_IN subjects_NNS included_VBN in_IN each_DT of_IN the_DT 1263W94_JJ dose_NN cohorts_NNS is_VBZ shown_VBN in_IN Table_NP ._SENT The_DT 62_CD subjects_NNS receiving_VBG 1263W94_JJ and_CC the_DT 16_CD subjects_NNS receiving_VBG the_DT placebo_NN were_VBD similar_JJ in_IN demographic_JJ characteristics_NNS ,_, in_IN CD4+_NP cell_NN count_NN ,_, and_CC in_IN Centers_NPS for_IN Disease_NP Control_NP and_CC Prevention_NP (_( CDC_NP )_) classification_NN status_NN at_IN baseline_NN ,_, as_RB shown_VBN in_IN Table_NP ._SENT Of_IN the_DT 78_CD subjects_NNS enrolled_VBN in_IN the_DT study_NN ,_, 70_CD completed_VBD the_DT 28-day_JJ dosing_VBG period_NN of_IN the_DT study_NN ._SENT Eight_CD subjects_NNS withdrew_VBD from_IN the_DT study_NN prematurely_RB ._SENT Of_IN these_DT eight_CD ,_, six_CD subjects_NNS (_( three_CD in_IN the_DT 200-mg_JJ t.i.d._JJ cohort_NN and_CC one_CD each_DT in_IN the_DT 600-_CD ,_, 900-_CD ,_, and_CC 1,200-mg_JJ b.i.d._JJ cohorts_NNS )_) discontinued_VBN due_RB to_TO adverse_JJ events_NNS ,_, consisting_VBG of_IN grade-2_JJ rash_NN (_( five_CD subjects_NNS )_) and_CC sinusitis_NN (_( one_CD subject_NN )_) ._SENT A_DT seventh_JJ subject_NN (_( in_IN the_DT 900-mg_NN b.i.d._NN cohort_NN )_) was_VBD withdrawn_VBN from_IN the_DT study_NN after_IN the_DT day-1_JJ hematology_NN results_NNS indicated_VBD neutropenia_NN (_( 400_CD cells/mm3_NN )_) ,_, and_CC an_DT eighth_JJ subject_NN (_( in_IN the_DT 900-mg_NN b.i.d._NN cohort_NN )_) withdrew_VBD from_IN the_DT study_NN on_IN day_NN 2_CD due_NN to_TO anxiety_NN about_IN the_DT serial_JJ PK_NP sampling_NN ._SENT Concomitant_JJ medications_NNS ._SENT |_SYM Subjects_NN were_VBD stable_JJ on_IN all_DT chronically_RB administered_VBN therapy_NN for_IN HIV_NP and_CC opportunistic_JJ infections_NNS for_IN at_IN least_JJS 1_CD month_NN prior_JJ to_TO receiving_VBG 1263W94_JJ ._SENT Most_JJS of_IN the_DT subjects_NNS were_VBD receiving_VBG concomitant_JJ medications_NNS that_WDT were_VBD CYP3A4_NP inhibitors_NNS ,_, such_JJ as_IN protease_NN inhibitors_NNS and_CC antifungal_JJ agents_NNS ._SENT One_CD subject_NN received_VBN efavirenz_NP ,_, a_DT CYP3A4_NP inducer_NN ._SENT PK_NP analysis_NN ._SENT |_SYM Descriptive_JJ statistics_NNS for_IN plasma_NN 1263W94_JJ PK_NP parameters_NNS are_VBP displayed_VBN in_IN Table_NP ._SENT There_EX was_VBD a_DT dose-proportional_JJ increase_NN in_IN plasma_NN 1263W94_JJ AUCinfinity_NN ,_, Cmax_NP ,_, and_CC AUC24,ss_NP over_IN the_DT dose_NN range_NN tested_VBD ,_, as_RB displayed_VBN in_IN Fig._NN ._SENT The_DT slope_NN estimates_VBZ (_( and_CC 90_CD %_NN CI_NP )_) for_IN plasma_NN 1263W94_JJ parameters_NNS were_VBD as_RB follows_VBZ :_: AUCinfinity_NP ,_, 1.12_CD (_( 0.98_CD ,_, 1.27_CD )_) ;_: AUC24,ss_NP ,_, 0.95_CD (_( 0.84_CD ,_, 1.06_CD )_) ;_: and_CC Cmax_NP ,_, 0.98_CD (_( 0.85_CD ,_, 1.10_CD )_) ._SENT 1263W94_NP demonstrated_VBD linear_JJ PK_NP ,_, with_IN steady-state_NN plasma_NN 1263W94_JJ profiles_NNS predictable_JJ based_VBN on_IN single-dose_JJ data_NNS as_IN demonstrated_VBN by_IN the_DT ratio_NN (_( and_CC 90_CD %_NN CI_NP )_) of_IN AUCtau,ss_NP to_TO AUCinfinity_NP ._SENT The_DT ratio_NN of_IN plasma_NN 1263W94_JJ AUCtau,ss_NP to_TO AUCinfinity_NP was_VBD close_JJ to_TO 1_CD ,_, and_CC the_DT associated_VBN 90_CD %_NN CI_NP was_VBD relatively_RB balanced_VBN on_IN either_DT side_NN of_IN 1_CD ,_, for_IN each_DT of_IN the_DT doses_NNS administered_VBN ._SENT The_DT percentage_NN of_IN the_DT dose_NN that_WDT was_VBD excreted_VBN in_IN urine_NN as_IN 1263W94_NP was_VBD minimal_JJ ;_: on_IN average_NN ,_, less_JJR than_IN 3_CD %_NN of_IN the_DT parent_NN compound_NN was_VBD eliminated_VBN in_IN urine_NN ._SENT Semen_NP 1263W94_JJ concentrations_NNS increased_VBN with_IN increasing_VBG doses_NNS ._SENT Median_JJ 1263W94_JJ concentrations_NNS in_IN semen_NN (_( with_IN the_DT range_NN and_CC number_NN of_IN subjects_NNS given_VBN in_IN parentheses_NNS )_) were_VBD as_RB follows_VBZ :_: for_IN the_DT 100-mg_JJ t.i.d._JJ cohort_NN ,_, 1.67_CD mug/ml_NN (_( 0.30_CD to_TO 3.53_CD ;_: n_NN =_SYM 9_CD )_) ;_: for_IN the_DT 200-mg_JJ t.i.d._JJ cohort_NN ,_, 2.96_CD mug/ml_NN (_( 2.54_CD to_TO 3.09_CD ;_: n_NN =_SYM 4_CD )_) ;_: for_IN the_DT 400-mg_JJ t.i.d._JJ cohort_NN ,_, 8.41_CD mug/ml_NN (_( 3.62_CD to_TO 25.57_CD ;_: n_NN =_SYM 9_CD )_) ;_: and_CC for_IN the_DT 900-mg_NN b.i.d._NN cohort_NN ,_, 11.85_CD mug/ml_NN (_( 3.42_CD to_TO 21.77_CD ;_: n_NN =_SYM 8_CD )_) ._SENT A_DT semen_NN 1263W94_JJ concentration_NN of_IN 6.22_CD mug/ml_NN was_VBD measured_VBN for_IN a_DT single_JJ subject_NN in_IN the_DT 600-mg_JJ b.i.d._JJ cohort_NN ._SENT Quantitation_NP of_IN HCMV_NP in_IN semen_NN and_CC whole_JJ blood_NN ._SENT |_SYM Figure_NN presents_VBZ changes_NNS from_IN baseline_NN in_IN semen_NN HCMV_NP amounts_NNS (_( based_VBN on_IN plaque_NN assays_NNS and_CC PCR_NP assays_NNS )_) for_IN subjects_NNS in_IN the_DT main_JJ group_NN at_IN days_NNS 4_CD (_( when_WRB applicable_JJ )_) ,_, 7_CD ,_, 14_CD ,_, 21_CD ,_, and_CC 28_CD ._SENT Based_VBN on_IN HCMV_NP titers_NNS ,_, subjects_NNS in_IN the_DT 200-mg_JJ t.i.d._NN (_( n_NN =_SYM 5_CD )_) and_CC the_DT 400-mg_JJ t.i.d._NN (_( n_NN =_SYM 6_CD )_) cohorts_NNS experienced_VBD the_DT greatest_JJS decreases_NNS in_IN HCMV_NP amounts_NNS ,_, with_IN a_DT mean_JJ decrease_NN at_IN day_NN 28_CD of_IN 3.7_CD log10_NN PFU/ml_NP (_( standard_JJ deviations_NNS [_SYM SD_NP ]_SYM ,_, 0.96_CD for_IN the_DT 200-mg_JJ t.i.d._JJ cohort_NN and_CC 1.08_CD for_IN the_DT 400-mg_JJ t.i.d._JJ cohort_NN )_) ,_, while_IN subjects_NNS in_IN the_DT 100-mg_JJ t.i.d._JJ cohort_NN (_( n_NN =_SYM 7_CD )_) experienced_VBD a_DT mean_JJ (_( +-SD_NN )_) decrease_NN of_IN 2.9_CD (_( +-0.79_NN )_) log10_NN PFU/ml_NN and_CC subjects_NNS in_IN the_DT 600-mg_JJ b.i.d._NN (_( n_NN =_SYM 6_CD )_) cohort_NN experienced_VBD a_DT mean_JJ (_( +-SD_NN )_) decrease_NN of_IN 3.3_CD (_( +-1.32_NN )_) log10_NP PFU/ml_NP ._SENT Quantitative_JJ reductions_NNS in_IN semen_NN HCMV_NP DNA_NP amounts_NNS and_CC the_DT differences_NNS between_IN the_DT cohorts_NNS were_VBD less_RBR pronounced_VBN than_IN for_IN HCMV_NP amounts_NNS as_RB measured_VBN by_IN titers_NNS ._SENT At_IN day_NN 28_CD ,_, mean_JJ decreases_NNS from_IN baseline_NN in_IN HCMV_NP DNA_NP amounts_NNS were_VBD 1.1_CD log10_NN copies/ml_NN for_IN the_DT 100-mg_JJ t.i.d._JJ cohort_NN (_( n_NN =_SYM 7_CD )_) ,_, 1.5_CD log10_NN copies/ml_NN for_IN the_DT 200-mg_JJ t.i.d._JJ cohort_NN (_( n_NN =_SYM 4_CD )_) ,_, and_CC 1.3_CD log10_NN copies/ml_NN for_IN both_CC the_DT 400-mg_JJ t.i.d._NN (_( n_NN =_SYM 5_CD )_) and_CC 600-mg_JJ b.i.d._NN (_( n_NN =_SYM 2_LS )_) cohorts_NNS ._SENT The_DT numbers_NNS (_( and_CC percentages_NNS )_) of_IN subjects_NNS in_IN each_DT cohort_NN with_IN >=2-log10-unit_NN reductions_NNS from_IN baseline_NN in_IN semen_NN HCMV_NP titers_NNS at_IN day_NN 28_CD were_VBD as_RB follows_VBZ :_: 6_CD of_IN 7_CD subjects_NNS (_( 86_CD %_NN )_) in_IN the_DT 100-mg_JJ t.i.d._JJ cohort_NN ,_, 5_CD of_IN 5_CD subjects_NNS (_( 100_CD %_NN )_) in_IN the_DT 200-mg_JJ t.i.d._JJ cohort_NN ,_, 6_CD of_IN 6_CD subjects_NNS (_( 100_CD %_NN )_) in_IN the_DT 400-mg_JJ t.i.d._JJ cohort_NN ,_, and_CC 5_CD of_IN 6_CD subjects_NNS (_( 83_CD %_NN )_) in_IN the_DT 600-mg_JJ b.i.d._JJ cohort_NN ._SENT Only_RB a_DT single_JJ subject_NN in_IN each_DT cohort_NN had_VBD a_DT >=2-log10-unit_NN reduction_NN in_IN semen_NN HCMV_NP DNA_NP concentrations_NNS from_IN baseline_NN to_TO day_NN 28_CD ._SENT Only_RB one_CD subject_NN ,_, who_WP received_VBD 1263W94_JJ at_IN 600_CD mg_NN b.i.d._NN ,_, had_VBD quantifiable_JJ HCMV_NP DNA_NN in_IN whole_JJ blood_NN at_IN baseline_NN (_( 4.81_CD log10_NN copies/ml_NN )_) ._SENT In_IN this_DT subject_JJ HCMV_NP DNA_NP amounts_NNS decreased_VBD to_TO below_IN the_DT limit_NN of_IN detection_NN by_IN the_DT PCR_NP assay_NN (_( <1.2_log10 =10_JJ %_NN of_IN subjects_NNS in_IN either_CC the_DT 1263W94_JJ or_CC the_DT placebo_NN group_NN ,_, and_CC the_DT numbers_NNS (_( and_CC percentages_NNS )_) of_IN subjects_NNS reporting_VBG the_DT event_NN in_IN the_DT 1263W94_JJ and_CC placebo_NN groups_NNS ,_, respectively_RB ,_, were_VBD as_RB follows_VBZ :_: taste_NN disturbances_NNS ,_, 51_CD (_( 82_CD %_NN )_) and_CC 3_CD (_( 19_CD %_NN )_) ;_: headache_NN ,_, 13_CD (_( 21_CD %_NN )_) and_CC 3_CD (_( 19_CD %_NN )_) ;_: diarrhea_NN ,_, 16_CD (_( 26_CD %_NN )_) and_CC 2_CD (_( 13_CD %_NN )_) ;_: nausea_NN ,_, 14_CD (_( 23_CD %_NN )_) and_CC 2_CD (_( 13_CD %_NN )_) ;_: rash_NN ,_, 12_CD (_( 19_CD %_NN )_) and_CC 1_CD (_( 6_CD %_NN )_) ;_: pruritus_NN ,_, 12_CD (_( 19_CD %_NN )_) and_CC 1_CD (_( 6_CD %_NN )_) ;_: fever_NN ,_, 7_CD (_( 11_CD %_NN )_) and_CC 0_CD ;_: exacerbation_NN of_IN fatigue_NN ,_, 6_CD (_( 10_CD %_NN )_) and_CC 2_CD (_( 13_CD %_NN )_) ;_: vomiting_NN ,_, 5_CD (_( 8_CD %_NN )_) and_CC 2_CD (_( 13_CD %_NN )_) ;_: constipation_NN ,_, 0_CD and_CC 2_CD (_( 13_CD %_NN )_) ;_: and_CC upper_JJ respiratory_JJ tract_NN infection_NN ,_, 2_CD (_( 3_CD %_NN )_) and_CC 2_CD (_( 13_CD %_NN )_) ._SENT Diarrhea_NN and_CC taste_NN disturbances_NNS appeared_VBD to_TO be_VB dose_NN related_VBN ._SENT After_IN approximately_RB 7_CD to_TO 12_CD days_NNS of_IN therapy_NN ,_, five_CD subjects_NNS receiving_VBG 1263W94_JJ prematurely_RB discontinued_VBN the_DT study_NN due_JJ to_TO a_DT drug-related_JJ diffuse_JJ maculopapular_JJ rash_NN of_IN moderate_JJ (_( grade-2_JJ )_) intensity_NN ._SENT Two_CD of_IN these_DT subjects_NNS received_VBD 200_CD mg_NN t.i.d._NN ,_, and_CC one_PP each_DT received_VBD 600_CD ,_, 900_CD ,_, and_CC 1,200_CD mg_NN b.i.d._NP Four_CD of_IN these_DT subjects_NNS had_VBD a_DT history_NN of_IN allergic_JJ reaction_NN to_TO other_JJ drugs_NNS ._SENT After_IN discontinuation_NN of_IN the_DT study_NN drug_NN ,_, the_DT rash_NN resolved_VBN within_IN approximately_RB 1_CD to_TO 4_CD days_NNS without_IN sequelae_NNS ._SENT Two_CD serious_JJ non-drug-related_JJ adverse_JJ events_NNS were_VBD reported_VBN during_IN the_DT study_NN ._SENT The_DT first_JJ event_NN was_VBD cholecystitis_NN ,_, for_IN which_WDT the_DT subject_NN underwent_VBD a_DT cholecystectomy_NN ._SENT The_DT second_JJ event_NN was_VBD a_DT single_JJ episode_NN of_IN pulmonary_JJ thromboembolism_NN ._SENT The_DT symptoms_NNS of_IN pulmonary_JJ thromboembolism_NN (_( dyspnea_NN and_CC chest_NN pain_NN )_) resolved_VBN within_IN 2_CD weeks_NNS of_IN hospital_NN admission_NN and_CC initiation_NN of_IN appropriate_JJ therapy_NN ._SENT Both_DT events_NNS occurred_VBN in_IN subjects_NNS who_WP received_VBD the_DT placebo_NN ._SENT Clinical_JJ laboratory_NN values_NNS for_IN subjects_NNS who_WP received_VBD 1263W94_JJ and_CC subjects_NNS who_WP received_VBD the_DT placebo_NN were_VBD not_RB significantly_RB different_JJ ,_, and_CC there_EX were_VBD no_DT dose-related_JJ trends_NNS in_IN clinical_JJ laboratory_NN values_NNS ._SENT Decreases_NNS in_IN lymphocytes_NNS and_CC increases_NNS in_IN total_JJ protein_NN were_VBD consistent_JJ with_IN the_DT HIV-infected_JJ status_NN of_IN the_DT subjects_NNS ,_, and_CC modest_JJ decreases_NNS in_IN hemoglobin_NN were_VBD consistent_JJ with_IN the_DT phlebotomy_NN requirements_NNS of_IN the_DT protocol_NN ._SENT Hemoglobin_NN values_NNS increased_VBN to_TO screening_VBG values_NNS by_IN the_DT 4-week_JJ poststudy_NN visit_NN ._SENT FIG._NN 1_CD ._SENT |_SYM Plots_NP of_IN dose_NN versus_CC plasma_NN 1263W94_JJ AUCinfinity_NN (_( a_DT )_) and_CC AUC24,ss_NP (_( b_LS )_) ._SENT Plots_NNS of_IN dose_NN versus_CC plasma_NN 1263W94_JJ AUCinfinity_NN (_( a_DT )_) and_CC AUC24,ss_NP (_( b_LS )_) ._SENT FIG._NN 2_CD ._SENT |_SYM (_( a_DT )_) Median_JJ concentration-time_JJ profiles_NNS of_IN HCMV_NP in_IN semen_NN ,_, measured_VBN in_IN PFU_NP per_IN milliliter_NN by_IN using_VBG plaque_NN assays_NNS ._SENT (_( a_DT )_) Median_JJ concentration-time_JJ profiles_NNS of_IN HCMV_NP in_IN semen_NN ,_, measured_VBN in_IN PFU_NP per_IN milliliter_NN by_IN using_VBG plaque_NN assays_NNS ._SENT Symbols_NNS :_: ,_, 100_CD mg_NN t.i.d._NN (_( n_NN =_SYM 7_CD )_) ;_: ,_, 200_CD mg_NN t.i.d._NN (_( n_NN =_SYM 5_CD )_) ;_: ,_, 400_CD mg_NN t.i.d._NN (_( n_NN =_SYM 6_CD )_) ;_: ,_, 600_CD mg_NN b.i.d._NN (_( n_NN =_SYM 6_CD )_) ._SENT (_( b_LS )_) Median_JJ concentration-time_JJ profiles_NNS of_IN HCMV_NP DNA_NP in_IN semen_NN ,_, measured_VBN in_IN log10_JJ copies_NNS per_IN milliliter_NN by_IN using_VBG PCR_NP analysis_NN ._SENT Symbols_NNS :_: ,_, 100_CD mg_NN t.i.d._NN (_( n_NN =_SYM 7_CD )_) ;_: ,_, 200_CD mg_NN t.i.d._NN (_( n_NN =_SYM 4_CD )_) ;_: ,_, 400_CD mg_NN t.i.d._NN (_( n_NN =_SYM 5_CD )_) ;_: ,_, 600_CD mg_NN b.i.d._NN (_( n_NN =_SYM 2_CD )_) ._SENT TABLE_NN 1_CD |_SYM Demographic_JJ and_CC baseline_JJ characteristics_NNS TABLE_NP 2_CD |_SYM Plasma_NP 1263W94_NP PK_NP parameters_NNS at_IN days_NNS 1_CD and_CC 28_RB There_EX is_VBZ a_DT need_NN to_TO develop_VB effective_JJ and_CC safe_JJ oral_JJ therapies_NNS for_IN the_DT treatment_NN and_CC prevention_NN of_IN HCMV_NP disease_NN ._SENT 1263W94_NP is_VBZ a_DT benzimidazole_NN riboside_NN with_IN potent_JJ and_CC selective_JJ inhibition_NN of_IN HCMV_NP in_IN vitro_NP and_CC with_IN limited_JJ cytotoxic_JJ and_CC toxicologic_JJ effects_NNS based_VBN on_IN in_IN vitro_NN and_CC in_IN vivo_JJ screenings_NNS ._SENT Pre-clinical_JJ studies_NNS have_VBP indicated_VBN that_IN 1263W94_NP has_VBZ good_JJ oral_JJ bioavailability_NN ._SENT This_DT study_NN was_VBD designed_VBN to_TO evaluate_VB the_DT PK_NP ,_, anti-HCMV_NP activity_NN ,_, safety_NN ,_, and_CC tolerability_NN of_IN 1263W94_JJ administered_VBN a_DT 